

# PATENT COOPERATION TREATY

# PCT

## INTERNATIONAL SEARCH REPORT

(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference <b>1770-235PCT</b>	<b>FOR FURTHER ACTION</b> <small>see Notification of Transmittal of International Search Report (Form PCT/ISA/220) as well as, where applicable, item 5 below.</small>	
International application No. <b>PCT/CA 00/ 01118</b>	International filing date (day/month/year) <b>28/09/2000</b>	(Earliest) Priority Date (day/month/year) <b>30/09/1999</b>
Applicant  <b>MCGILL UNIVERSITY</b>		

This International Search Report has been prepared by this International Searching Authority and is transmitted to the applicant according to Article 18. A copy is being transmitted to the International Bureau.

This International Search Report consists of a total of 4 sheets.

☒ It is also accompanied by a copy of each prior art document cited in this report.

### 1. Basis of the report

- a. With regard to the **language**, the international search was carried out on the basis of the international application in the language in which it was filed, unless otherwise indicated under this item.

☐ the international search was carried out on the basis of a translation of the international application furnished to this Authority (Rule 23.1(b)).

- b. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international search was carried out on the basis of the sequence listing :

☒ contained in the international application in written form.

☒ filed together with the international application in computer readable form.

☐ furnished subsequently to this Authority in written form.

☐ furnished subsequently to this Authority in computer readable form.

☐ the statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.

☐ the statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished

2. ☒ **Certain claims were found unsearchable** (See Box I).

3. ☐ **Unity of invention is lacking** (see Box II).

4. With regard to the **title**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established by this Authority to read as follows:

5. With regard to the **abstract**,

☒ the text is approved as submitted by the applicant.

☐ the text has been established, according to Rule 38.2(b), by this Authority as it appears in Box III. The applicant may, within one month from the date of mailing of this international search report, submit comments to this Authority.

6. The figure of the **drawings** to be published with the abstract is Figure No.

☐ as suggested by the applicant.

☐ because the applicant failed to suggest a figure.

☐ because this figure better characterizes the invention.

☒ **None of the figures.**

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/CA 00/01118

**A. CLASSIFICATION OF SUBJECT MATTER**  
 IPC 7 C12Q1/68 A61P43/00 A61K31/525

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12Q A61P A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	AKERMAN B ET AL: "Trimethylaminuria is caused by mutations of the FM03 gene in North American Cohort" MOLECULAR GENETICS AND METABOLISM, vol. 68, no. 1, September 1999 (1999-09), pages 24-31, XP001053087 Table 1 and "Results."	1-9, 11-16
X	ORPHAN A ET AL: "THE EFFECT OF ARGENINE-428 MUTATION ON MODULATION OF ACTIVITY OF HUMAN LIVER FLAVIN MONOOXYGENASE 3 (FM03) BY IPRAMINE AND CHLOROPROMAZINE" EXPERIMENTAL PATHOLOGY, vol. 51, no. 4-5, July 1999 (1999-07), pages 271-76, XP001053062 the whole document	1-9, 11-15



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*G\* document member of the same patent family

Date of the actual completion of the international search

30 January 2002

Date of mailing of the international search report

13/02/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
 Fax: (+31-70) 340-3016

Authorized officer

Osborne, H

# INTERNATIONAL SEARCH REPORT

International Application No

CA 00/01118

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	TREACY E ET AL: "Mutations of the flavin-containing monooxygenase gene (FMO3) cause trimethylaminuria, a defect in detoxication" HUMAN MOLECULAR GENETICS, vol. 7, no. 5, 1998, pages 839-45, XP002188745 table 1	1-9, 11-16
A	FR 2 756 845 A (GENSET SA) 12 June 1998 (1998-06-12) claims 21-23	17,18

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/CA 00/01118

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Although claims 17,18 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/CA 00/01118

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
FR 2756845	A	12-06-1998	FR 2756845 A1	12-06-1998
			AU 5327198 A	29-06-1998
			EP 0941341 A1	15-09-1999
			WO 9824914 A1	11-06-1998
			JP 2001505430 T	24-04-2001

# PATENT COOPERATION TREATY

PCT

## NOTICE INFORMING THE APPLICANT OF THE COMMUNICATION OF THE INTERNATIONAL APPLICATION TO THE DESIGNATED OFFICES

(PCT Rule 47.1(c), first sentence)

From the INTERNATIONAL BUREAU

To: COTE, France  
Swabey Ogilvy Renault  
Suite 1600  
1981 McGill College Avenue  
Montréal, Québec H3A 2Y3  
CANADA

SWABEY OGILVY RENAULT

MONTELEONE

RECEIVED

APR 19 2001

7 8 9 10 11 12 1 2 3 4 5 6

Date of mailing (day/month/year) 05 April 2001 (05.04.01)		IMPORTANT NOTICE	
Applicant's or agent's file reference 1770-235PCT			
International application No. PCT/CA00/01118	International filing date (day/month/year) 28 September 2000 (28.09.00)	Priority date (day/month/year) 30 September 1999 (30.09.99)	
Applicant MCGILL UNIVERSITY et al			

1. Notice is hereby given that the International Bureau has communicated, as provided in Article 20, the international application to the following designated Offices on the date indicated above as the date of mailing of this Notice:  
AU,KP,KR,US

In accordance with Rule 47.1(c), third sentence, those Offices will accept the present Notice as conclusive evidence that the communication of the international application has duly taken place on the date of mailing indicated above and no copy of the international application is required to be furnished by the applicant to the designated Office(s).

2. The following designated Offices have waived the requirement for such a communication at this time:  
AE,AG,AL,AM,AP,AT,AZ,BA,BB,BG,BR,BY,BZ,CA,CH,CN,CR,CU,CZ,DE,DK,DM,DZ,EA,EE,EP,ES,FI,GB,GD,GE,GH,GM,HR,HU,ID,IL,IN,IS,JP,KE,KG,KZ,LC,LK,LR,LS,LT,LU,LV,MA,MD,MG,MK,MN,MW,MX,MZ,NO,NZ,OA,PL,PT,RO,RU,SD,SE,SG,SI,SK,SL,TJ,TM,TR,TT,TZ,UA,UG,UZ,VN,YU.  
The communication will be made to those Offices only upon their request. Furthermore, those Offices do not require the applicant to furnish a copy of the international application (Rule 49.1(a-bis)).
3. Enclosed with this Notice is a copy of the international application as published by the International Bureau on 05 April 2001 (05.04.01) under No. WO 01/23603

### REMINDER REGARDING CHAPTER II (Article 31(2)(a) and Rule 54.2)

If the applicant wishes to postpone entry into the national phase until 30 months (or later in some Offices) from the priority date, a demand for international preliminary examination must be filed with the competent International Preliminary Examining Authority before the expiration of 19 months from the priority date.

It is the applicant's sole responsibility to monitor the 19-month time limit.

Note that only an applicant who is a national or resident of a PCT Contracting State which is bound by Chapter II has the right to file a demand for international preliminary examination.

### REMINDER REGARDING ENTRY INTO THE NATIONAL PHASE (Article 22 or 39(1))

If the applicant wishes to proceed with the international application in the national phase, he must, within 20 months or 30 months, or later in some Offices, perform the acts referred to therein before each designated or elected Office.

For further important information on the time limits and acts to be performed for entering the national phase, see the Annex to Form PCT/IB/301 (Notification of Receipt of Record Copy) and Volume II of the PCT Applicant's Guide.

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer J. Zahra
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

# PATENT COOPERATION TREATY

## PCT

### NOTIFICATION OF ELECTION

(PCT Rule 61.2)

From the INTERNATIONAL BUREAU

To:

Commissioner  
US Department of Commerce  
United States Patent and Trademark  
Office, PCT  
2011 South Clark Place Room  
CP2/5C24  
Arlington, VA 22202  
ETATS-UNIS D'AMERIQUE  
in its capacity as elected Office

Date of mailing (day/month/year) 04 July 2001 (04.07.01)	Applicant's or agent's file reference 1770-235PCT
International application No. PCT/CA00/01118	Priority date (day/month/year) 30 September 1999 (30.09.99)
International filing date (day/month/year) 28 September 2000 (28.09.00)	
Applicant TREACY, Eileen, P. et al	

1. The designated Office is hereby notified of its election made:

☒ in the demand filed with the International Preliminary Examining Authority on:

26 April 2001 (26.04.01)
☐ in a notice effecting later election filed with the International Bureau on:
2. The election ☒ was
☐ was not

made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO  
34, chemin des Colombettes  
1211 Geneva 20, Switzerland

Facsimile No.: (41-22) 740.14.35

Authorized officer

Nestor Santesso

Telephone No.: (41-22) 338.83.38

CA0001118

## PCT

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

8

Applicant's or agent's file reference 1770-235PCT FC	<b>FOR FURTHER ACTION</b> See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/CA00/01118	International filing date (day/month/year) 28/09/2000	Priority date (day/month/year) 30/09/1999
International Patent Classification (IPC) or national classification and IPC C12Q1/68		
Applicant MCGILL UNIVERSITY et al.		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.


2. This REPORT consists of a total of 6 sheets, including this cover sheet.

- ☐ This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☒ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand  26/04/2001	Date of completion of this report  12.06.2002
Name and mailing address of the international preliminary examining authority:  European Patent Office D-80298 Munich Tel. +49 89 2399 - 0 Tx: 523656 epmu d Fax: +49 89 2399 - 4465	Authorized officer  Barz, W  Telephone No. +49 89 2399 7320





# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA00/01118

## I. Basis of the report

1. With regard to the **elements** of the international application (*Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17)*):

### Description, pages:

1-39 as originally filed

### Claims, No.:

1-18 as originally filed

### Drawings, sheets:

1/1 as originally filed

### Sequence listing part of the description, pages:

1-3, as originally filed

2. With regard to the **language**, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language: , which is:

- ☐ the language of a translation furnished for the purposes of the international search (under Rule 23.1(b)).
- ☐ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of a translation furnished for the purposes of international preliminary examination (under Rule 55.2 and/or 55.3).

3. With regard to any **nucleotide and/or amino acid sequence** disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☒ contained in the international application in written form.
- ☒ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. The amendments have resulted in the cancellation of:

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT**

International application No. PCT/CA00/01118

- ☐ the description,      pages:  
☐ the claims,      Nos.:  
☐ the drawings,      sheets:

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed (Rule 70.2(c)):

*(Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.)*

6. Additional observations, if necessary:

**III. Non-establishment of opinion with regard to novelty, inventive step and industrial applicability**

1. The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

- ☐ the entire international application.  
☒ claims Nos. 17-18.

because:

- ☒ the said international application, or the said claims Nos. 17-18 relate to the following subject matter which does not require an international preliminary examination (*specify*):  
**see separate sheet**
- ☐ the description, claims or drawings (*indicate particular elements below*) or said claims Nos. are so unclear that no meaningful opinion could be formed (*specify*):
- ☐ the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
- ☐ no international search report has been established for the said claims Nos. .

2. A meaningful international preliminary examination cannot be carried out due to the failure of the nucleotide and/or amino acid sequence listing to comply with the standard provided for in Annex C of the Administrative Instructions:

- ☐ the written form has not been furnished or does not comply with the standard.  
☐ the computer readable form has not been furnished or does not comply with the standard.

**V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/CA00/01118

## 1. Statement

Novelty (N)	Yes:	Claims	17-18
	No:	Claims	1-16
Inventive step (IS)	Yes:	Claims	
	No:	Claims	1-18
Industrial applicability (IA)	Yes:	Claims	1-16
	No:	Claims	

## 2. Citations and explanations see separate sheet

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/CA00/01118

**ITEM III:**

**Claims 17-18** relate to subject-matter considered by this Authority to be covered by the provisions of Rule 67.1(iv) PCT. Consequently, no opinion will be formulated with respect to the industrial applicability of the subject-matter of these claims (Article 34(4)(a)(i) PCT). See, however, item V-3. below.

**ITEM V:**

Reference is made to the following documents:

- D1: MOLECULAR GENETICS AND METABOLISM, vol. 68, no. 1,  
September 1999, pages 24-31; (Akerman B.R. et al.);  
D2: HUMAN MOLECULAR GENETICS, vol. 7, no. 5, 1998, pages 839-45;  
(Treacy E.P. et al.).

**1. NOVELTY**

**Claims 1-16** do not meet the requirements of Article 33(2) PCT for the following reasons:

- 1.1 Methods for detecting an altered metabolism of a substrate of a FMO in a patient, comprising all the features of present **claim 1**, are disclosed in documents D1 (abstract; tables 1-2; figure 1; discussion) and D2 (abstract; pages 840-841; tables 1 and 3; discussion). Therefore, the subject-matter of claim 1 is not novel in the sense of Article 33(2) PCT.
- 1.2 Similarly, the detection methods comprising all features of present **claims 2-4** are also known from D1 (abstract; tables 1-2; page 27, last paragraph; discussion) and D2 (abstract; page 840, second paragraph; page 843, right column, lines 10-14), thereby destroying novelty of said claims (Article 33(2) PCT).

**INTERNATIONAL PRELIMINARY  
EXAMINATION REPORT - SEPARATE SHEET**

---

International application No. PCT/CA00/01118

- 1.3 The dependent **claims 5-16** are also not new, because their additional features are also disclosed in D1 (abstract; tables 1-2; figure 1; discussion) and D2 (abstract; pages 840-841; tables 1 and 3; discussion).
- 1.4 The remaining **claims 17-18** appear to be novel, because the available prior art does not disclose methods for treating individuals having a FMO-associated disorder.

**2. INVENTIVE STEP**

However, **claims 17-18** do not appear to be inventive in the sense of Article 33(3) PCT for the following reasons: Document D1, which is considered to represent the closest prior art, discloses the association between altered FMO3 activity and FMO-associated disorders (such as TMAuria). Compared to said prior art document, the subject-matter of present **claims 17-18** differs only in that the individual having such a disorder is treated by supplementing the individual with riboflavin. Since, however, it is well-known to the skilled person that riboflavin is the cofactor for all FAD-dependent enzyme (including the FMO enzyme family), it would be obvious to the skilled person to supplement an affected individual with riboflavin, thereby arriving at the subject-matter of said claims. Thus, the subject-matter of claims 17-18 does not appear to involve an inventive step and does not satisfy the criterion set forth in Article 33(3) PCT.

**3. INDUSTRIAL APPLICABILITY**

For the assessment of the present **claims 17-18** on the question whether they are industrially applicable, no unified criteria exist in the PCT Contracting States. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subject-matter of claims to the use of a compound in medical treatment, but may allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
**WO 01/23603 A2**

(51) International Patent Classification<sup>7</sup>: **C12Q 1/68**

(21) International Application Number: **PCT/CA00/01118**

(22) International Filing Date:  
28 September 2000 (28.09.2000)

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
60/156,934 30 September 1999 (30.09.1999) **US**

(71) Applicant (for all designated States except US): **MCGILL UNIVERSITY** [CA/CA]; 845 Sherbrooke West, Montréal, Québec H3A 2T5 (CA).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **TREACY, Eileen, P.** [CA/CA]; 462 Elm Avenue, Westmount, Québec H3Y 3J1 (CA). **AKERMAN, Beverly, R.** [CA/CA]; 6076 Notre-Dame de Grace, Montréal, Québec H4A 1N2 (CA).

(74) Agents: **COTE, France et al.; Swabey Ogilvy Renault**, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

**Published:**

— Without international search report and to be republished upon receipt of that report.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/23603 A2

(54) Title: **HUMAN FMO3 GENE MUTATIONS AND POLYMORPHISMS, AND USES THEREOF**

(57) Abstract: The present invention relates to human *FMO3* gene polymorphisms and more particularly to uses thereof in the diagnosis of trimethylaminuria. There is provided a method for detecting an altered metabolism of a substrate of a flavin-containing monooxygenase form 3 (*FMO3*) enzyme in an individual, detecting a susceptibility of an individual to a substrate of the *FMO3* enzyme in an individual, and for detecting a predisposition of an individual to a disorder associated with an exposure to a heteroatom-containing chemical compound, by detecting mutations or polymorphic variants of the *FMO3* gene.

HUMAN FMO3 GENE MUTATIONS AND POLYMORPHISMS,  
AND USES THEREOF

BACKGROUND OF THE INVENTION

5 (a) Field of the Invention

The invention relates to human FMO3 gene polymorphisms and mutations, and more particularly to uses thereof in pharmacogenomics and the diagnosis of inborn errors of metabolism such as trimethylaminuria and predisposition to hypertension.

10 (b) Description of Prior Art

Inter-individual variations resulting in population-wide differences in the metabolism of foreign compounds or xenobiotics may contribute to the susceptibility of humans to adverse chemicals or drug reactions and disease states. Most incidences of genetic variation can be accounted for by more prevalent alleles such as alleles with a frequency of greater than 1% in the general population, called polymorphisms or common variants. It is probable that common variants may contribute in a significant fashion to disease susceptibility. Pharmacogenomics allows for the identification of genetic variation in drug-metabolizing enzymes and the identification of individuals who will benefit most or least from a given medication.

Detoxification of xenobiotics including drugs, food additives and environmental chemicals is mediated by Phase I (oxidative) and Phase II (conjugative) reactions. The microsomal cytochrome P450 (CYP) family of monooxygenases is highly polymorphic in humans. CYP3A4 is largely responsible for hepatic drug metabolism. However, CYP2D6 metabolizes a variety of widely prescribed drugs, and individuals with impaired CYP2D6 activity show a number of drug interactions

resulting from aberrant metabolism due to inactivating polymorphisms.

Human flavin-containing monooxygenases (FMO) (EC 1.14.13.8) are microsomal NADPH-dependent flavoprotein enzymes that catalyze the oxygenation of nucleophilic nitrogen-, sulfur-, phosphorus- and other heteroatom-containing chemicals, drugs and pesticides. The FMOs belong to the FSSP flavocytochrome c sulfide dehydrogenase subfamily of flavoenzymes, NAD(P)H-dependent monooxygenases and reductases. FMOs are membrane-bound proteins that have been detected in all secretory cell types that have been examined. Human FMOs are 532-558 amino acids in length, with specific amino acids highly conserved in all species, particularly residues 4-32 and 186-213, which contain the FAD and NADPH-binding domains, respectively (Cashman J (1995) Chem Res Toxicol 8:166-181). The amino acid sequence identity between human isoforms is at a minimum of 52%. FMO enzymes have a broad substrate specificity compared to other mammalian monooxygenases, with at least 1,000 known substrates for these enzymes. They represent a family of five monooxygenases in mammals designated FMO, forms 1-5.

Differences in drug metabolism among animal species have been recognized for more than 50 years. Human FMO drug metabolizing enzymes are thought to have evolved as a multi-gene family from an original monooxygenase such as that cloned and characterized from yeast (*Saccharomyces cerevisiae*) which has high amino acid sequence conservation with mammalian FMO.

Of the five FMO monooxygenase enzymes, FMO3 constitutes the prominent form that converts nucleophilic heteroatom-containing chemicals and endogenous materials to polar, readily excreted oxygenated metabolites, and this facilitates their



elimination. *FMO3* constitutes the major adult human hepatic isoform. Biogenic amines including primary amines, such as tyramine and phenylethylamine, and tertiary amines are good substrates for human *FMO3* (Cashman J (1995) Chem Res Toxicol 8:166-181). Tertiary amine substrates include trimethylamine (TMA), antihistamines, and (S)-nicotine. TMA and tyramine are N-containing substrates of the enzyme. Commonly used drugs such as tricyclic antipsychotics, cimetidine, ranitidine, albendazole and verapamil are also oxygenated by human *FMO3* (Cashman J (1995) Chem Res Toxicol 8:166-181, Ziegler, 1990).

The odorous, dietary-derived tertiary amine trimethylamine (TMA) is N-oxygenated by human *FMO3* to the non-odorous trimethylamine N-oxide (TMANO). TMANO is excreted in a detoxication and deodoration process. In normal humans, over 95% of TMA is metabolized to TMANO and is excreted in the urine at concentrations of less than 18  $\mu\text{mol}$  of TMA/ $\text{mmol}$  creatinine under normal dietary conditions. In a small number of humans, TMA is not efficiently metabolized to TMANO, and those individuals suffer from trimethylaminuria or fish-like odor syndrome, due to the presence of relatively large amounts of this odorous volatile amine in bodily excretions, including urine, sweat and breath.

Trimethylaminuria (TMAuria), first described in 1970, is an autosomal recessive inborn error of metabolism, which results in a partial or total inability to oxidize TMA to TMANO. (Treacy EP et al. Hum Molec Genet 7: 839-845, 1998) and a severe body odor reminiscent of rotten fish emanating in sweat, breath and urine with associated psychosocial disorders. This condition, previously thought to be rare, is now being increasingly detected in severe and

milder presentations. TMAuria occurs in Australians and has a predicted incidence of ~1/40,000 in North Americans.

Current treatment strategies include dietary  
5 restriction of TMA precursors (choline, lecithin and carnitine), the intermittent use of antibiotics such as metronidazole, and other supportive measures.

Treatment options for this condition are limited and not well studied. Current strategies  
10 include limitation of choline and TMA precursors. Dietary restrictions are insufficient for a number of individuals (related to genotype). Also some individuals over restrict choline which may also cause side-effects.

15 A number of individuals are consuming severely protein-restricted diets. Choline is an essential amine required for synthesis of phosphatidylcholine, sphingomyelin, acetylcholine and betaine (essential for remethylation of homocysteine) and for  
20 myelination. Choline deficiency causes memory impairment, liver and kidney dysfunction and cell death by apoptosis.

In 1998, choline was classified as an essential human nutrient by the Food and Nutrition Board of the  
25 Institute of Medicine of the National Academy of Sciences. Choline intake requires careful assessment in children and expectant mothers. There is as yet no studies of choline requirements in individuals with TMAuria on and off diet, and the precise choline  
30 limitation required for satisfactory decreases of TMA levels and relief of symptoms has never been studied. Choline and derivatives such as phosphocholine are present in many food stuffs including milk and infant formulas in a substantial amount (25). Precise  
35 definition of choline requirements in individuals with

TMAuria would be useful to determine a choline-restricted formula.

The structure for the *FMO3* gene has been characterized and maps to chromosome 1q23-25. The *FMO3* gene is approximately 28 kb in length, with 1 noncoding and 8 coding exons (Gene Bank Accession Number AL021026).

Although substrates are generally detoxicated by *FMO*-mediated metabolism, the *FMO3* enzyme has been implicated in the bioactivation of a number of xenobiotics (Cashman J (1995) Chem Res Toxicol 8:166-181). Thus, inactivating variants or polymorphisms of human *FMO3* may contribute to the pathophysiology of diseases and adverse reactions or exaggerated clinical responses to specific medications.

There exist genotyping assays which predict altered drug metabolism for the parallel phase I drug metabolizing enzyme system cytochrome P450.

There are at present no clinical tests available for pharmacogenomics with respect to *FMO3* and no markers for altered predisposition to handling of *FMO3* substrates.

It would therefore be highly desirable to be provided with a diagnostic test for trimethylaminuria.

It would also be highly desirable to be provided with identified pharmacogenomic polymorphisms of *FMO3*. The detection of same would allow the determination of differential responses to medications and environmental toxins related to diseases such as those involving a complex pathophysiology. A large scale screening of the population with the detection of same would be advantageous to the pharmaceutical industry. The upregulation or downregulation of such polymorphic genotypes may also be made possible.

### SUMMARY OF THE INVENTION

One aim of the present invention is to provide a diagnostic test for trimethylaminuria (TMAuria).

Another aim of the present invention is to  
5 provide identified polymorphisms of *FMO3*. The identified polymorphisms may allow the determination of differential responses to medications and environmental toxins causing diseases.

Mutations of the *FMO3* gene have been determined  
10 to cause trimethylaminuria.

Several single nucleotide polymorphisms (SNPs) of the *FMO3* gene have been identified. Rare mutations were discovered and identified use of the mutations and polymorphisms to determine their consequences for  
15 detoxication of drugs, chemicals and endogenous materials is also provided.

The distribution of the three polymorphisms V257M, E158K and E308G was studied in different combinations in Quebec individuals (Genetic  
20 Signatures). *In vitro* expression analysis in an *E. coli* system indicated that the codon 158 and 257 polymorphisms are pharmacogenomic, prevalent polymorphisms. Preliminary clinical evidence is provided to the effect that the E308G polymorphism,  
25 particularly when in *cis* with the variant codon 158 allele, alters oxidation of trimethylamine, likely applicable to other *FMO3* substrates. Analysis of cDNA expressed *FMO3*-maltose-binding fusion proteins for two of those polymorphisms demonstrated altered N-  
30 oxygenation for 10-(N'-N-dimethylaminopentoyl)-2-(trifluoromethyl) phenothiazine, indicating that these are significant pharmacogenomic polymorphisms.

Diagnostic tests for the mutations and polymorphisms are provided. The study of the  
35 distribution and population frequency of these three

polymorphisms (pharmacogenomics) may likely predict adverse or altered response to typical *FMO3* substrates and common medications and indicate predispositions to complex disorders associated with disordered xenobiotic and biogenic amine metabolism. Expression analysis for the third polymorphism may be effected.

Loss of N-oxygenation and decreased clearance of amine-containing chemicals or drugs may contribute to adverse drug reactions, interactions with catecholamine or exaggerated clinical response to specific medications.

The detection of *FMO3* polymorphisms may be used to determine differential responses to medications and environmental toxins applicable to complex disease pathophysiology, and to determine high throughput screening for polymorphism detection (DNA chip technology) for large scale population, which may be advantageous to the pharmaceutical industry. Polymorphic *FMO3* genotypes may also be upregulated or downregulated.

In accordance with the present invention, there is provided a method for detecting an altered metabolism of a substrate of a flavin-containing monooxygenase (FMO) enzyme or an isoform thereof in an individual. The method comprises detecting at least one of a mutation and a polymorphic variant of a gene encoding the FMO enzyme or isoform thereof in a sample from the individual, whereby the at least one of the mutation and the polymorphic variant is indicative of an altered metabolism for the substrate.

In accordance with the present invention, there is also provided a method for detecting a susceptibility of an individual to a substrate of the FMO enzyme or isoform thereof in an individual. The method comprises detecting at least one of a mutation

and a polymorphic variant of a gene encoding the FMO enzyme or isoform thereof in a sample from the individual, whereby the at least one of the mutation and the polymorphic variant is indicative of a susceptibility to the substrate.

In accordance with the present invention, there is further provided a method for detecting a predisposition of an individual to a disorder associated with an (adverse) exposure to a heteroatom-containing chemical compound, an intermediate or a metabolite thereof associated with carcinogenesis or having a toxic, pro-carcinogenic or carcinogenic potential. The method comprises detecting at least one of a polymorphic variant and a mutation of a gene encoding the FMO enzyme or an isoform thereof in a sample from the individual, whereby the at least one of the polymorphic variant and the mutation is indicative of exposure to the chemical compound, the intermediate or the metabolite thereof.

In accordance with the present invention, there is further provided a method for detecting a predisposition to hypertension in a patient, the method comprising detecting at least one of a mutation and a polymorphic variant of a gene encoding the FMO enzyme in a sample from the patient, whereby at least one of the mutation and the polymorphic variant is indicative of a predisposition to hypertension.

In accordance with the present invention, there is further provided a method for the treatment of an individual having a disorder associated with an altered activity of the FMO enzyme or an isoform thereof. The method comprises supplementing the individual with riboflavin to increase the altered activity of the FMO enzyme or the isoform thereof.

The mutation or polymorphic variant may inactivate partially or totally the activity of the FMO enzyme.

The isoform of the enzyme may consist of form 3  
5 (FMO3).

The polymorphic variant may comprise a polymorphic variant from the group consisting of E158K, V257M and E308G, and the mutation may comprise a mutation from the group consisting of P153L, E305X,  
10 M66I, E314X, R492W, A52T and R387L.

The altered metabolism may be associated with an idiosyncratic reaction to the substrate.

The altered metabolism may be associated with a disorder such as a cancer. The disorder may also be  
15 TMAuria.

The substrate may consist of a xenobiotic or an endogenous material relative to the individual. The xenobiotic may be a drug, a food additive, a pesticide, a plant toxin, an organic chemical compound  
20 or an aromatic amine. The substrate may be a biogenic amine contained in the individual's diet. The biogenic amine may consist of a tertiary amine, such as trimethylamine (TMA), tyramine or catecholamine.

For the purpose of the present invention, the  
25 following abbreviations are defined below.

"FMO" is intended to mean human flavin-containing monooxygenase;

"FMO3" is intended to mean human flavin-containing monooxygenase form 3;

30 "FMO1" is intended to mean human flavin-containing monooxygenase form 1;

"TMA" is intended to mean trimethylamine;

"TMANO" is intended to mean trimethylamine N-oxide;

"5-APT" is intended to mean 10-(5-Aminopentyl)-  
35 2(trifluoromethyl)phenothiazine;

"5-DPT" is intended to mean 10-(N,N-Dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine;  
MBP: maltose binding protein;

"FMO3 MBP" is intended to mean human flavin-containing  
5 monooxygenase form 3 maltose binding protein;

"SDS-PAGE" is intended to mean sodium dodecyl sulfate  
polyacrylamide gel electrophoresis;

"TCA" is intended to mean trichloroacetic acid; and

"TMAuria" is intended to mean trimethylaminuria.

10 A "polymorphism" is intended to mean a  
nucleotide substitution of a gene that occurs at a  
frequency greater than 1% in individuals in the  
general population.

"Severe" TMAuria is intended to mean a  
15 reduction of TMA oxidation below 50% of normal  
oxidation.

A "genetic signature" with respect to a  
substitution is intended to mean a combination of a  
polymorphism or a mutation identified in an individual  
20 or haplotype for the substitution of interest.

The term "patient" is intended to mean a mammal  
preferably human.

#### **BRIEF DESCRIPTION OF THE DRAWINGS**

25 Fig. 1 illustrates in a diagram the  
structural organization of FMO3 cDNA.

#### **DETAILED DESCRIPTION OF THE INVENTION**

Two mutations of the FMO3 gene, P153L and E305X  
30 (OMIM accession numbers 136132.001 and 136132.004)  
account for greater than 90% of cases of TMAuria in  
Australians. Six other mutations (Fig. 1) and three  
intragenic polymorphisms (E158K, V257M and E308G)  
which appear to affect TMA and other FMO3 substrate  
35 oxidation are also reported. In a North-American



cohort (including 4 Canadians) 100% ascertainment of mutant alleles was reported and in some probands, the second mutant allele comprises two of these polymorphisms in cis, (K158-G308) (Akerman BR et al. 5 Am J Hum Genet (1997) Supplement to vol 61 (no. 4). Abs. no.281) (Table 1). Of the three polymorphisms identified in Quebec (see Table 2), expression of mutant cDNAs for the codon 158 and 257 polymorphisms showed altered N-oxygenation for 5-DPT (a 10 phenothiazine substrate), tyramine and TMA, suggesting that these polymorphisms are significant prevalent pharmacogenomic polymorphisms.

A cohort of individuals was ascertained in North America with severe TMAuria.

15 Of 70 referrals for a suspected diagnosis of TMAuria, TMAuria was confirmed in 20 individuals with reduced TMANO/TMA ratios. (Normal values are: TMANO/TMA relative % ratios>98:2). Among these, some had symptoms of hypertension and migraine with 20 abnormal dopamine metabolism, suggesting that mutations of the *FMO3* gene may result in abnormal catecholamine metabolism.

Four new *FMO3* mutations were detected in this cohort: two missense (A52T and R387L), and one 25 nonsense (E314X) (Akerman BR et al. Am J Hum Genet (1997) Supplement to vol 61 (no. 4). Abs. no.281). The fourth allele is apparently composed of two relatively common polymorphisms (K158-G308) found in the general population.

30 A number of prevalent nucleotide polymorphisms of the human *FMO3* gene were identified. Polymorphisms that are prevalent in French Canadian and Australian populations were studied. The cDNA-expression analysis for two of these prevalent human *FMO3* polymorphisms 35 showed altered N-oxygenase activities, indicating that

these are significant pharmacogenomic polymorphisms.

Two prevalent polymorphisms of this gene (E158K and V257M) modulate the activity of human *FMO3*. These polymorphisms are widely distributed in Canadian and Australian Caucasian populations. *In vitro* analysis of wild-type and variant human *FMO3* proteins expressed from the cDNA for these two naturally-occurring polymorphisms showed differences in substrate affinities for nitrogen-containing substrates. Thus, for polymorphic forms of human *FMO3*, lower  $k_{cat}/K_m$  values for N-oxygenation of 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine, trimethylamine and tyramine were observed. The results imply that prevalent polymorphisms of the human *FMO3* gene likely represent low penetrance predispositions to diseases associated with adverse environmental exposures to heteroatom-containing chemicals, drugs and endogenous amines.

Analysis of polymorphisms may be performed by PCR testing in Quebec residents with application to metabolism of *FMO3* substrates (medications) in humans that are heterozygous or homozygous for polymorphisms. The genotyping methods are described herein. The genotypes observed in Quebec (Genetic Signatures) and methods thereof are also described. Deficient human *FMO3* N-oxygenase activity has implications for the abnormal metabolism of many other endogenous dietary and medicinal amines.

We previously reported that the enzyme encoded by the human *FMO3* Glu158 polymorphic allele is more active for the tertiary amine substrates TMA and 5-DPT than the enzyme encoded by the less prevalent human *FMO3* Lys158 allele (Treacy EP et al. Hum Molec Genet 7: 839-845, 1998).

Two new other polymorphisms are provided herein. The presence of these prevalent *FMO3* polymorphisms implies that some individuals may be more susceptible to the effects of environmental chemicals and to idiosyncratic drug reactions. Thus, if a drug or chemical is dependent on human *FMO3* for detoxication and if an individual possesses a impaired polymorphic form of *FMO3* then the drug or chemical may produce an exaggerated clinical response and this could lead to adverse reactions.

Human *FMO1* is not functionally active in adult human liver (Cashman J (1995) Chem Res Toxicol 8:166-181). Based on the kinetic parameters observed, human *FMO1* does not appear to make a significant contribution to the metabolism of TMA. From the present results it is likely that human *FMO1* does not 'rescue' an individual that is deficient in *FMO3* from suffering the consequences of trimethylaminuria. Human *FMO1* does not significantly N-oxygenate primary amines such as tyramine or 5-APT but can participate in the N-oxygenation of chemicals or drugs containing the tertiary amine functionality.

From the *in vitro* data, the codon 257 polymorphism appears to show substantial differences in kinetics for the biogenic amine substrate, tyramine and the dietary amine, TMA. This may have clinical consequences.

The maintenance of the prevalent codon 158 polymorphism in the Caucasian populations examined may not result solely from genetic drift, but perhaps as a consequence of molecular drive, whereby particular polymorphisms with selective advantages persist, for example, to combat exposure to plant toxins in particular geographic regions. The distribution of the two codon 158 alleles is almost in equilibrium in

these populations, suggesting that this may be an older polymorphism that is now balanced. Human *FMO3* V257M is of lower prevalence and may represent a founder effect.

5           Variation in human drug metabolism by genetic polymorphisms may increase the risk for acquiring exposure-related disease, including cancer, with important public health consequences. Generally, oxidative metabolism of heteroatom-containing  
10 compounds by CYP-dependent processes leads to production of chemical intermediates with increased potential for toxic or carcinogenic properties. Although human *FMOs* generally convert lipophilic heteroatom-containing compounds to polar, readily  
15 excreted oxygenated metabolites that possess decreased toxic potential, they may also catalyze the N-oxygenation of a wide array of xenobiotics such as plant toxins, organic chemicals and aromatic amines associated with carcinogenesis (Cashman J (1995) *Chem*  
20 *Res Toxicol* 8:166-181).

Consistent with the fact that human drug-metabolizing enzymes have endogenous substrates and are prevalent not as neutral balanced polymorphisms but for their selective advantages, it was previously  
25 shown that human *FMO3* metabolizes biogenic amines such as tyramine and phenethylamine resulting in great stereoselectivity of their oxime metabolites. Formation of oxime metabolites generally terminates the pharmacological activity of the parent amine (Lin,  
30 J et al. (1997) *Chem. Res. Toxicol.* 10: 842-852). It is shown herein that the methionine variant at codon 257 of human *FMO3* shows decreased N-oxygenation for the substrate tyramine. Tyramine is an indirectly-acting sympathomimetic that exerts its pressor effect  
35 through amine uptake into the sympathetic nervous

system with release of norepinephrine from synaptic vesicles. It is thus possible that human *FMO3* polymorphisms affecting tyramine or other biogenic amine metabolism may predispose humans to variable tolerance to tyramine or other biogenic amine-containing foods and associated symptoms.

It is shown that human *FMO3* null alleles are rare and cause a severe phenotype with lack of oxygenation of human *FMO3* substrates such as TMA (Cashman JR et al. Chem Res Toxicol 10:837-841, 1997; Treacy EP et al. Hum Molec Genet 7: 839-845, 1998). On the basis of the in vitro data described herein, the human *FMO3* polymorphisms have been shown to have milder effect on N-oxygenation activity. The polymorphisms are, however, of higher frequency, and thus they are more likely to show specific associations with complex diseases in populations.

The present invention will be more readily understood by referring to the following examples which are given to illustrate the invention rather than to limit its scope.

#### EXAMPLE I

**TMAuria is caused by mutations of the *FMO3* gene in a North American Cohort**

##### **25 Urine detection**

Early morning first void samples were collected and acidified with N HCl to pH 2 upon collection from subjects, and TMA and TMANO were measured by fast atom bombardment mass spectrometry using <sup>16</sup>N-labeled TMA and TMANO as internal standards, a highly sensitive assay.

Values were expressed as mmole TMA or TMANO per mole creatinine. Control ratios for 20 adult urine collected from volunteers were established as TMANO:TMA percentage ratios > 98:2%.

**Mutation detection**

DNA was extracted by standard methods from whole blood collected in EDTA from probands with TMAuria. The samples were then screened by PCR and restriction digestion for amino acid polymorphisms previously identified (E158K, V257M and E308G) and for mutations detected in the Australian TMAuria cohort (M66I, P153L, E305X, R492W).

Table 1 lists conditions used for the restriction diagnostic tests performed and the relevant primer sequences.

**Table 1**  
**Diagnostic PCR Reactions**  
**for human HFMO3 Variants**

Allele	Exon	Primers (sense-antisense; 5' to 3')	SEQ ID No:	Restriction enzyme	Expected normal (bp)	Pattern mutant (bp)
A52T	3	2038: GACCTGATCAGTATACTCATTTA 2025: AATGGGAAGTCTGGGAAACACTT	1 2	<i>NheI</i>	79	147
M66I	3	As above		<i>MseI</i>	147	122 25
P153	4	2055: TTGTTCCGGACATCATGTGTAGC Gen2: TCCCTGCTGTGGAAGCATT	3 4	<i>AluI</i>	263 66	263 45 21
K158E	4	As above		<i>HinfI</i>	253 76	217 76 36
V257M	6	C1: TTCCAGAAGTGGCTCCTGGG 2005: GCTTGAATCTGCATTCATCTGC	5 6	<i>Hsp92II</i>	97 60	72 60 25
E305X	7	2019: CCTTATCAATTTATATATGGACC 2016: GGACCTTGTAAGTAGGATTATTG	7 8	<i>EcoRI</i>	365 164	529
E308G	7	As above		<i>BsaI</i>	362 167	529
E314X	7	As above		<i>AclI</i>	409 122	532
R387L	7	As above		<i>MseI</i>	112 102	102 88
R492W	9	2049: GAAATGCCATACTGACCCCATGG 2050: TAGCAAAGCCCCTGTCTGGGTAT	9 10	<i>BstXI</i>	211	24 186 25

To confirm the three newly identified mutations, restriction enzyme analysis was performed on three independent PCR products from the probands. For the A52T and R387L alleles, the mutations ablated naturally-occurring restriction sites, while the E314X variant created a new restriction site, as shown in

Table 1. The mutation assays were subsequently used to determine the frequency of mutations in control samples from the province of Quebec, Canada.

### Results

5           Of 28 individuals referred for investigation of TMAuria, we identified 10 who had a marked decrease in TMA oxidation, with less than 50% of the total TMA in the N-oxide form, as shown in (Table 2). Control ratios for these compounds were defined as being  
10 greater than 98:2% in our laboratory. Further analysis was possible for 10 of the remaining undiagnosed consultants by gas chromatography-mass spectrometry; no abnormalities were detected. In addition, testing  
15 of these 10 urine samples by NMR spectroscopy ruled out dimethylglycinuria, a recently described entity which also presents with a fish-like odor and mild TMAuria.

          Four of the parents of our defined TMAuria probands (obligate heterozygotes) were also tested for  
20 TMANO:TMA ratios. For one heterozygote carrying the E314X mutation the TMANO:TMA ratio was noted to be 95:5. For the other heterozygotes carrying missense mutations the values obtained (without a TMA challenge) were observed to be in the normal range  
25 (data not shown).

          Of the 10 probands with perturbed TMANO:TMA ratios, DNA was available from 8 individuals; mutation analysis was performed on these samples. The ethnic origins as well as the *FM03* genotypes of these are  
30 detailed in Table 2: 7 of the probands are of European Caucasian origin; one is Metis (French Canadian/North American Indian).

**Table 2**  
**FM03 Mutations and Phenotypes**  
**in Eight Proband with TMAuria**

Subject (sex)	Age <sup>a</sup>	Ethnic origin	Biochemical phenotype			Genotype <sup>e</sup>	
			TMANO <sup>c</sup>	TMA <sup>b</sup>	TMANO: TMA	Nucleotide change	Amino acid Change
1 <sup>d</sup> (M)	55	Irish/ English	33.90	50.71	39:61	458G>T-(472G)/ 458G>T(472G)	P153L-(E158)/ P153L-(E158)
2 (F)	28	German/ German Irish/ French	17.86	22.73	44:56	154G>A-(472A)- 923A>G/ (472A)-923A>G	A52T-(K158)- E308G/(K158)- E308G
3 (M)	23	German/ Russian	6.05	66.2	8.4:91.6	458G>T-(472G)/ (472G)-1923A>G	P153L-(E158)/ (E158)-E308G- E314X
4 <sup>c</sup> (M)	12	German	11.31	60.24	16:84	458G>T-(472A)/ 458G>T-(472A)	P153L-(K158)/ P153L-(K158)
5 <sup>c</sup> (M)	10	Metis	5.47	65.34	8:92	(472A)-1160G>T/ (472A)-1160G>T	(K158)-R387L/ (K158)-R387L
6 (M)	11	English	6.93	51.90	12:88	458G>T/(472G)/ (472G)-913G>T	P153L-(E158)/ (E158)-E305X
7 (F)	8	French Canadian	12.20	75.8	14:86	458G>T/1474C>T/ (472G/A)	P153LR492W;
8 (M)	2	English	8.36	52.96	14:86	458G>T(472G)/ 458G>T(472G)	(158 E/K)P153L (E158)

5

<sup>a</sup> Age at diagnosis.<sup>b</sup> Units are mmol TMA or TMANO/mol creatinine.<sup>c</sup> Indicates the presence of migraine.<sup>d</sup> Ischemic heart disease.10 <sup>e</sup> In addition to the mutations, the genotype at polymorphic codon 158 is given in parentheses.<sup>f</sup> Normal values: TMANO > 98% total, TMA < 2% total.

Of previously described mutations, P153L was found to account for nine alleles in this study, while the E305X and R492W mutations were each observed uniquely. M66I, previously observed in the Australian cohort, was not detected in this study. Four new disease-causing alleles were detected: A52T (c.154G→A), E308G (c.923A→G), E314X (c.940G→T), and R387L (c.1160G→T). The substitutions A52T, E314X, and



R387L were not detected on screening 60 control chromosomes from French Canadians. The E308G allele was found to segregate in two probands, homozygous in one compounded with another missense allele (A52T).  
5 The G308 allele was detected in 36/198 normal control chromosomes from a Quebec francophone population ( $q=0.18$ ) and in 18 of 118 chromosomes of a Quebec anglophone population ( $q=0.15$ ). We observed E308G in the homozygous state in one French Canadian control.  
10 The allele frequency of the G308 allele in probands (0.19) is not statistically different from the background frequency.

Thus, 10 cases of severe TMAuria were confirmed in 28 North Americans with the presenting symptom of  
15 malodor. The results are similar to those of the group of George Preti in Philadelphia, who reported that one-third of their referrals for the same complaints were due to TMAuria. While our report defines cases of severe TMAuria, it does not address the possible  
20 phenotype of heterozygotes or very mild cases which may be detected by TMA or choline challenge testing. All of the probands studied have TMA oxidation of less than 50% of normal.

A relationship between ablation of FMO3  
25 activity and symptoms suggestive of disordered biogenic amine metabolism such as hypertension has been noted. In this study, 3 to 10 TMAuria probands also exhibit "labile" hypertension according to their physicians, although one of these individuals (Table  
30 2, Subject 1) also has ischemic heart disease which may cause secondary hypertension. Three of the 10 confirmed subjects report the symptoms of classical migraine, a condition noted to be associated with disordered metabolism of biogenic amines such as  
35 tyramine. As FMO3 is expressed in brain and

metabolizes biogenic amines, this association merits further study.

It is now established that mutation of the *FMO3* gene causes severe TMAuria in North American probands. 5 100% ascertainment of mutations in cases defined by the admission criteria of the study are reported. Our previous studies of Australian TMAuria probands detected two relatively common mutations (P153L and E305X) in probands of British origin and two rare 10 alleles (M66I, R492W). In this North American cohort, it also found that the mutation P153L is relatively frequent, accounting for 9 of 16 mutant chromosomes. The segregation of the alleles E305X and R492W was also noted. These alleles may have originated in the 15 British Isles.

Four new mutations were detected. The alleles A52T, E314X, and R387L may be "private" mutations, as they have been observed once in the probands of differing ethnic backgrounds. Loss of activity is 20 strongly predicted from truncation of the *FMO3* protein at codon 314 since we know that deletion of even the final 30 amino acids of this 582 residue protein will ablate function *in vitro* (Cashman J (1995) Chem Res Toxicol 8:166-181). While the mutations A52T and R387L 25 have not been expressed, they satisfy several conditions for designation as disease-causing: the changes have not been observed in controls ( $n=30$ ), they are nonconservative substitutions, and no other changes were identified in the probands on sequencing 30 all expressed *FMO3* exons. The A52 and R387 residues appear to be highly conserved within the *FMO* gene family, as seen in Table 3.

**Table 3**  
**Amino Acid Sequence Surrounding Human FMO3**  
**Codons 52 and 387; Identity and Variation**  
**among Other FMO Proteins**

HFMO3a partial amino acid sequence

Enzyme	A	E	E	G	R	A52	S	I	Y	K	Reference
RbFMO3	-	*	*	*	*	*	*	*	*	Q	(35)
MFMO3	I	*	*	*	*	*	*	*	*	*	(36)
GpFMO5	P	*	*	*	*	*	*	*	*	*	(37)
HFMO5	P	*	*	*	*	*	*	*	*	*	(37)
HFMO1	V	*	*	*	*	*	*	L	*	*	(38)
MFMO1	V	*	*	*	*	*	*	L	*	*	D16215 <sup>b</sup>
PFMO1	V	*	*	*	*	*	*	L	*	*	(39)
RtFMO1	V	*	*	*	*	*	*	L	*	N	(40)
GpFMO1	V	*	D	*	*	*	*	*	*	*	(41)
RhFMO2	V	*	D	*	*	*	*	*	*	Q	U59453 <sup>b</sup>
HFMO4	S	K	D	*	M	T	R	V	*	*	(42)
RbFMO4	S	K	D	*	M	T	R	V	*	W	(35)

HFMO3<sup>a</sup> partial amino acid sequence

Enzyme	V	D	L	Q	S	R387	W	A	A	Q	Reference
RbFMO3	T	*	*	*	A	*	*	*	*	*	(35)
MFMO3	T	*	*	*	A	*	*	*	*	*	(36)
GpFMO5	S	E	*	*	G	*	*	*	V	*	(37)
HFMO5	S	E	*	*	G	*	*	*	T	*	(37)
HFMO1	G	E	T	*	A	*	*	*	V	R	(38)
MFMO1	G	E	T	*	A	*	*	V	V	*	D16215 <sup>b</sup>
PFMO1	G	*	T	*	A	*	*	*	V	R	(39)
RtFMO1	G	E	T	*	A	*	*	V	V	*	(40)
GpFMO1	*	E	*	*	A	*	*	*	T	R	(41)
RhFMO2	A	E	*	*	A	*	*	V	T	R	U59453 <sup>b</sup>
HFMO4	T	E	*	*	A	*	*	V	T	R	(42)
RbFMO4	T	E	*	*	A	*	*	*	T	R	(35)

<sup>a</sup> Abbreviations: Gp, guinea pig; H, human; M, mouse; P, pig; Rb, rabbit; Rh, Rhesus monkey; Rt, rat.  
<sup>b</sup> GenBank Accession Number.

A comparison of amino acid sequences surrounding these residues in 12 published FMO sequences indicates that R387 is conserved in all 12 while the alanine at codon 52 is conserved in 10 of these 12. The variation at codon 52 seen in the 2 published FMO4 sequences may contribute to substrate specificity differences seen between FMO isoforms.

The G variant at codon 308 was observed in two probands with TMAuria. Subject 2 is an E308G homozygote with a single copy of the A52T missense mutation; Subject 3 is a compound heterozygote, with

E308G and E314X on one homologue and P153L in trans (Table 2). The G308 allele was originally observed segregating in normal controls, and it exists as a frequent polymorphism in the Quebec population (q=0.18). The E308G polymorphism may also mediate other variations of drug and chemical detoxication. The genotype for Subject 2, who has had complete sequencing of all FMO3 coding exons, is T52-K158-G308 on one allele and A52-K-158-G308 on the other. Previous in vitro expression studies on the codon 158 polymorphism indicated the K158 form of the protein is a poorer TMA N-oxygenator than the E158 form. The findings demonstrate that the G308 change on the K158 background functions as a TMAuria mutation. It is possible that these two common changes in cis further diminish the activity of the enzyme and render it incapable of compensating for the A52T mutant, resulting in a severe TMAuria phenotype.

As shown in Fig. 1, mutations appear to cluster in exon 7, with three of the four identified changes in this exon occurring within a 10 amino acid "hot spot". These changes fall near or in the areas of high homology described by Ziegler. They are in close proximity to the FATGY signature found in all the mammalian enzymes, while the R387L mutation is found in an area highly conserved among FMOs, strongly suggesting that this substitution affects protein function.

Each of the eight genotypically defined probands studied was ascertained in a different region of North America; presumably these regions differ in background carrier frequencies for FMO3 mutations. Since one of the probands is from Quebec, the overall population frequency question was addressed by screening for known mutations (M66I, P153L, E305X,

R492W) in a Quebec control group. Of 320 control chromosomes, only one carrier for the mutation E305X was detected. Although the number surveyed is small, this predicts that severe TMAuria should be rare in Quebec. Milder variations that may manifest with a precursor load may be more common. This condition may "cluster" in specific regions of the United States and Canada due to "founder effect" and "genetic drift", as occurs in the Melbourne region of Australia. In addition to possible evolutionary advantages in detoxication, there are other hypotheses to account for the maintenance of mutant *FMO3* alleles in the population. These must include other possible selective advantages of heterozygosity, perhaps in blood pressure homeostasis or in metabolism of choline, now recognized to be a vital amine involved in many pathways of intermediary metabolism

## **EXAMPLE II**

### **Population Specific Polymorphisms of the human *FMO3* gene: Significance for Detoxication**

#### **Study Population**

The human *FMO3* polymorphisms E158K (c.488 G-A) and V257M (c.769 G-A) were previously identified in a cohort of individuals with trimethylaminuria and normal controls from Melbourne, Australia using single stranded conformational polymorphism (SSCP) screening and sequencing of the *FMO3* gene (Treacy EP et al. Hum Molec Genet 7: 839-845, 1998). Following institutional ethics approval, the frequency of these substitutions were determined in 170 normal control individuals from Quebec (i.e., 110 Francophones and 60 Anglophones) and 50 normal controls from Victoria, Australia. Genomic DNA was prepared from lymphocyte preparations using

standard procedures. Amplified DNA fragments obtained by the polymerase chain reaction were subjected to restriction enzymatic digestion, and visualized by ethidium bromide staining after agarose or polyacrylamide gel electrophoresis. Table 1 illustrates the conditions used for each diagnostic assay.

**Table 4**  
Diagnostic PCR methods created to screen for identified human *FMO3* sequence changes among healthy controls

Allele	Oligonucleotide Sequence	SEQ ID NO:	Restriction Enzyme	Normal Restriction Pattern (bp)	Variant Restriction Pattern (bp)
<b>E158K</b>	2055: 5'-TTG TTC CGG ACA TCA TGT GTA GC -3'	3	<i>HinfI</i>	253	217
	Gen2: 5'-TCC CTG CTG TGG AAG CAT TT -3'	4		76	76
<b>V257M</b>	C1: 5'-TTC CAG AAG TGG CTC CTG GG -3'	5	<i>Hsp92II</i>	97	36
				60	72
	2005:5'-GCT TGA ATC TTG CAT TCA TCT GC -3'	6			60
					25

**Table 5**  
Genotype frequencies for the human *FMO3* polymorphisms E158K and V257M in Quebec, Canada and Victoria, Australia

	E158K	V257M
<b>QUEBEC FRANCOPHONE POPULATION</b>	N=109	N=108
	EE:38	VV:101
	EK:56	VM:6
	KK:15	MM:1
<b>QUEBEC ANGLOPHONE POPULATION</b>	N=60	n=58
	EE:16	VV:55
	EK:30	VM:3
	KK:14	
<b>VICTORIA</b>	N=39	N=61
	EE:12	VV:50
	EK:20	VM:9
	KK:78	MM:2

#### Data Analysis

The statistical significance of the frequency of the human *FMO3* E158K and V257M polymorphisms between Canadians (i.e., Anglophones and Francophones) and Australians was calculated. A chi-squared analysis

was used for human *FMO3* E158K to test the hypothesis that the proportion of chromosomes was not significantly different between the three groups of English Canadians, French Canadians and Australians ( $\chi$  squared, 2df = 2.52,  $p$  = 0.28). The Mantel-Haenszel test for small sample size was used for human *FMO3* V257M. There was no significant difference observed between the presence of the variant alleles in the three cohorts ( $\chi$  squared, 2df = 4.71,  $p$  = 0.095).

#### 10 Chemicals

[<sup>3</sup>H]-Tyramine was obtained from American Radioactivity Company (St. Louis, MO) and [<sup>14</sup>C]-TMA was obtained from Sigma Chemical Co., (St. Louis, MO). All chemicals and reagents were purchased from Aldrich Chemical Co. (Milwaukee, WI) in the highest purity commercially available.

#### Synthesis

10-(5-Aminopentyl)-2-(trifluoromethyl) phenothiazine (5-APT), its hydroxylamine and *cis* and *trans* oximes were synthesized by a modification of the procedures previously described. The tertiary amine 10-(N,N-dimethylaminopentyl)-2-(trifluoromethyl)phenothiazine (5-DPT) and its N-oxide was also synthesized by a procedure similar to the one previously described. The hydroxylamine and *cis* and *trans* oximes of tyramine were synthesized as previously described (Lin, J et al. (1997) Chem. Res. Toxicol. 10: 842-852).

#### cDNA-expression and Substrate Analysis

30 The human *FMO3* cDNAs were expressed as maltose binding fusion proteins. Site-directed mutagenesis for the human *FMO3* substitutions E158K and V257M were performed as previously described (Treacy EP et al. Hum Molec Genet 7: 839-845, 1998, Cashman JR et al.

Chem Res Toxicol 10:837-841, 1997]. For purposes of comparison, a cDNA construct for the truncation variants E305X (previously reported) and 510X were also prepared as the maltose binding protein fusions.

5    **Subcloning Human FMO1 and FMO3 cDNA into the Maltose Binding Protein Fusion Expression System**

Human FMO3 or FMO1 cDNA was inserted into the expression vector pMAL-c2 and PCR amplification was done in a fashion that allowed for fusion of human  
10 FMO3 or FMO1 cDNA at the 3'-end of sequences encoding the maltose binding protein (MBP) as previously described (Treacy EP et al. Hum Molec Genet 7: 839-845, 1998). Each cDNA was individually cloned and confirmed by oligonucleotide sequencing of both  
15 strands. The creation and cDNA-expression of wild type Glu 158 and the common polymorphic form Lys158 FMO3-MBPs has been previously described (Treacy EP et al. Hum Molec Genet 7: 839-845, 1998, Cashman JR et al. Chem Res Toxicol 10:837-841, 1997). Another  
20 polymorphic form of human FMO3 (i.e., Met 257) was created by oligonucleotide-directed mutagenesis and PCR in a similar fashion as described before. The truncation mutations of FMO3-MBP (E305X and 510X) were created by PCR. The template was the pMAL-2c wild type  
25 human FMO3 Glu 158 expression plasmid. At the appropriate position, the forward PCR primer contained a BamHI site that was followed by ATG. The reverse primer changed the codon following the site of truncation to an ochre stop codon, that was also part  
30 of a Hind III site. The truncated human FMO3 cDNA was synthesized using Taq polymerase under standard conditions. The PCR fragment was gel purified, digested with BamHI and HindIII and inserted with DNA ligase into the pMAL-c2 vector cut with the same  
35 restriction enzymes. Each desired truncation product



was transformed into competent JM109 *E. coli* and plated onto LB-Amp plates. DNA isolated from colonies were shown to contain the desired truncation mutation by sequencing of both strands. The truncation  
5 expression plasmids introduced into bacterial strain JM109 were purified by affinity chromatography as previously described.

### Electrophoresis and Immunoblotting

Overproduction of the affinity-purified human  
10 *FMO3*-MBP fusion proteins and truncation variants was shown by fractionation on 12% sodium dodecyl sulfate polyacrylic gel electrophoresis (SDS-PAGE). Immunoblots were done according to a previously  
15 described procedure using an affinity purified rabbit polyclonal antibody that was directed against the wild type human *FMO3*-MBP fusion protein.

### Enzyme Assays

Assay and analysis of human *FMO3*-MBP fusion protein and analysis of N-oxygenation activity for the  
20 variant enzymes was done by a procedure described previously. The N-oxygenation 5-APT was done using an HPLC method essentially identical to the one described previously for a closely related compound. TMA and  
25 tyramine N-oxygenation was determined using radiometric assays described below.

For [<sup>3</sup>H]-tyramine and [<sup>14</sup>C]-TMA, incubations were carried out in 13 x 100 screw-cap culture tubes suspended in a 37°C water bath-metabolic shaker apparatus. The reaction mixture consisted of 10-30 µg  
30 of human *FMO3*-MBP or variant, 0.05 M potassium phosphate buffer (pH = 8.4), 0.8 mM diethylenetriaminepentaacetic acid (DETAPAC), 0.5 mM NADP<sup>+</sup>, 0.5 mM glucose-6-phosphate and 1 IU of glucose-6-phosphate dehydrogenase in a total volume of 0.25  
35 ml. The reaction was initiated by the addition of

radiolabelled substrate to an ice-cold previously equilibrated enzyme solution, capped and incubated at 37°C with constant shaking. For TMA, the reaction was stopped by the addition of 0.25 ml cold CH<sub>3</sub>CN containing 0.01 ml trichloroacetic acid (TCA). For tyramine, the reaction was stopped by the addition of 0.25 ml cold MeOH. The incubation mixture was thoroughly mixed and centrifuged and an aliquot was applied to the loading zone of a Whatman Diamond LK6DF TLC plate (Clifton, NJ) previously co-spotted with authentic starting material or products of the specified reaction. For TMA, after air drying, the plate was developed in methanol/chloroform/20% TCA (90:10:0.5, v:v). The following bands ( $R_f$ ) were visualized by treating with iodine and scraped into scintillation vials for counting: TMA N-oxide (0.32) and TMA (0.08). For tyramine, after air drying, the plate was developed in methanol/dichloromethane/formic acid (20:80:0.2, v:v). The following bands ( $R_f$ ) were visualized by UV-vis and scraped into scintillation vials for counting: *cis* and *trans* phenylacetone oximes (0.84), tyramine hydroxylamine (0.35) and tyramine (0.04). Each vial was counted in a Beckman LS-2000 scintillation counter and the percent product formation was computed from the data for calculation of the kinetic parameters.

#### FAD determination

A 0.5 ml aliquot of protein was combined with an equivalent amount of cold acetonitrile, mixed and centrifuged at 12,000 x g. The pellet was washed three times with cold acetonitrile. To the protein pellet was added 50 µl of trifluoroacetic acid, mixed thoroughly and heated in a sealed tube at 55°C for at least 40 min. At the end of the reaction 100 µl of cold acetonitrile was added as well as a sufficient

amount of  $\text{NH}_4\text{OH}$  to neutralize the reaction. A portion of the mixture was injected directly onto a Hitachi HPLC system using a Rainin Microsorb MV C-18 reverse phase column (Rainin, Emeryville, CA). An eluent of water (containing 0.05%  $\text{HClO}_4$ ) for the first 20 min followed by  $\text{CH}_3\text{CN}$  (containing 0.05%  $\text{HClO}_4$ ) thereafter was used to separate FAD from other minor impurities by HPLC. FAD eluted during the first phase of the gradient and was detected at 450 nm with a retention time of 9.2 min. The amount of FAD was determined from a comparison of peak heights from a standard curve of FAD.

## RESULTS

### Genotype Frequencies

The genotype frequencies for the two prevalent human *FMO3* polymorphisms E158K, and V257M in healthy populations from Quebec, Canada and Victoria, Australia are listed in Table 5. On the basis of statistical analysis, the distribution of the two codon 158 polymorphic variants were found to be similar in Quebec Francophones and Anglophones and in the Australian population. Although the numbers were small, the methionine variant involving codon 257 appeared to be at higher frequency in the Australian population compared with the Quebec population.

### Substrate N-Oxygenation

Previous studies showed that non-transformed host bacteria or bacteria transformed with *pMal* alone did not contain any detectable human FMO activity when grown in the presence or absence of IPTG. Previously, it was shown that the relative activity of human *FMO3* MBP and some variants showed varying degrees of TMA N-oxygenation activity (Treacy EP et al. Hum Molec Genet 7: 839-845, 1998, Cashman JR et al. Chem Res Toxicol 10:837-841, 1997). To examine this point more

carefully and to quantify differences among the cDNA-expressed alleles,  $K_m$  and  $V_{max}$  values were obtained from double reciprocal plots of velocity versus substrate concentration. For the substrates examined, the formation of tertiary amine N-oxide, hydroxylamine or oxime metabolite was a linear function of protein concentration and with incubation time for at least 10 min. As shown by the kinetic constants listed in Table 4, wild-type human *FMO3* MBP efficiently N-oxygenated 5-DPT, TMA and tyramine. Activities for human *FMO1* MBP (a fetal hepatic *FMO* isoform that is expressed in adult kidney and intestine but not in adult liver) were evaluated in a similar kinetic fashion. The kinetic constants are listed in Table 6 for comparison. Human *FMO1* MBP N-oxygenated 5-DPT with a very low  $K_m$  value. In contrast, TMA N-oxygenation was significant but the concentration of substrate required for half-maximal activity of *FMO1* MBP was 15-fold greater than that of human *FMO3* MBP. The  $K_m$  for human *FMO1* MBP N-oxygenation of TMA compared favorably with that of TMA N-oxygenation for pig *FMO 1* (Cashman J (1995) Chem Res Toxicol 8:166-181).

**Table 6**  
**Kinetic Constants for Human FMO1 MBP, FMO3 MBP,**  
**and Variants of Human FMO3 MBP<sup>a</sup>**

5

Enzyme	$K_m$	$k_{cat} (min^{-1})$	$V_{max}/K_m^c$	Substrate
Human FMO1 (n=6)	$8.0 \pm 2.4$	$4.0 \pm 1.6$	0.5	5-DPT
<b>Human FMO3</b>				
(WT) Glu158 (n=3)	$154.9 \pm 31.8$	$50.7 \pm 1.6$	0.33	5-DPT
Lys158 (n=3)	$187.5 \pm 34.1$	$44.4 \pm 17.7$	0.23	5-DPT
Met257 (n=3)	$82.3 \pm 41.7$	$13.2 \pm 4.6$	0.16	5-DPT
510X (n=4)	$61.6 \pm 12.9$	$0.09 \pm 0.09$	0.001	5-DPT
Human FMO1 (n=4)	$486 \pm 34.8$	$25.9 \pm 3.7$	0.05	TMA
<b>Human FMO3</b>				
(WT) Glu158 (n=4)	$32.3 \pm 7.1$	$189 \pm 21$	5.85	TMA
Lys158 (n=4)	$206 \pm 21$	$105 \pm 3.8$	0.51	TMA
Met257 (n=4)	$1151 \pm 107$	$28.2 \pm 5.1$	0.02	TMA
510X (n=4)	$1034 \pm 139$	$34.9 \pm 14.6$	0.03	TMA
Human FMO1 (n=4)	ND <sup>b</sup>			Tyramine
<b>Human FMO3 (n=4)</b>				
(WT) Glu158 (n=4)	$231 \pm 43.4$	$110 \pm 16.1$	0.48	Tyramine
Lys158 (n=4)	$941 \pm 103$	$106.1 \pm 4.6$	0.11	Tyramine
Met257 (n=4)	$2164 \pm 87$	$41.3 \pm 6.8$	0.02	Tyramine
510X (n=4)	$1384 \pm 110$	$11.4 \pm 6.9$	0.008	Tyramine

<sup>a</sup>product determined by HPLC or radiometric assay. <sup>b</sup>Not Detectable, limit of detection; *trans* oxime, 20 pmol/min/mg of protein. <sup>c</sup> $V_{max}$  is given as nmol/min/nmol of protein, nmol of protein determined on the basis of FAD content as described in the Methods.

A prevalent polymorphic form of human FMO3, FMO3 MBP Lys 158, N-oxygenated 5-DPT, TMA and tyramine with higher  $K_m$  values and with a lower  $V_{max}$ . Another polymorphic variation of FMO3, FMO3 MBP Met 257, showed significant differences in the kinetic parameters for 5-DPT, TMA and tyramine. For 5-DPT, TMA and tyramine N-oxygenation, the  $V_{max}/K_m$  ratios for

human FMO1 MBP were 18-, 249- and 25-fold lower, respectively, than the  $V_{max}/K_m$  ratios for the wild type human FMO3 MBP enzyme.

Previously, we have examined the truncation mutation human FMO3 MBP 305X (Treacy EP et al. Hum Molec Genet 7: 839-845, 1998). No detectable N-oxygenase activity was observed for 5-DPT, TMA and tyramine. For comparison, a human FMO3 cDNA construct that was truncated at codon 510 was also analyzed for substrate N-oxygenation activity with 5-DPT, TMA and tyramine. The  $K_m$  values for FMO3 MBP 510X were similar to the  $K_m$  values observed for FMO3 MBP Met 257, but generally, the  $V_{max}$  values were significantly lower than the wild type fusion protein (Table 6).

The Glu 158 wild type human FMO3 MBP enzyme N-oxygenated 5-APT (i.e., the primary amine analog of 5-DPT) with a rate of 117 nmol/min/nmol of protein. As determined by HPLC, the major product was the hydroxylamine. A minor amount of oxime was formed and the ratio of *cis:trans* oxime was 79:21. Human FMO3 MBP Lys158 N-oxygenated the primary amine 5-APT with a rate of 69.1 nmol/min/nmol of protein. As determined by HPLC, the major product was the hydroxylamine. A minor product was the oxime and it was formed in a ratio of *cis:trans* oxime 81:19. By comparison, the human FMO3 Met 257 enzyme N-oxygenated the primary amine 5-APT with a rate of 28.1 nmol/min/nmol of protein. As determined by HPLC, the major product was the hydroxylamine. A minor product was the oxime and it was formed with a *cis:trans* stereoselectivity of 80:20. Human FMO1 MBP did not significantly N-oxygenate tyramine or 5-APT.

Because 5-APT was present in large excess, the rates were determined at saturating substrate concentration and represent apparent  $V_{max}$  values. We

examined a number of human *FMO3* MBP truncation mutations introduced between codon 305 and the wild type length. There was no significant N-oxygenase activity observed for the human *FMO3* cDNA construct with a truncation less than codon 510. Similar experiments have been conducted with pig *FMO1* MBP and a similar structure-function relationship has been observed (Cashman J (1995) Chem Res Toxicol 8:166-181).

### EXAMPLE III

#### **TMAuria and variation of the *FMO3* Gene Dietary and Pharmacogenomic Implications**

The relationships between choline (precursor of trimethylamine (TMA)), TMA and choline products (phosphatidylcholine, acetylcholine) in individuals with trimethylaminuria (TMAuria, OMIM 602079) and normal controls may be characterized to determine the optimum dietary treatment and choline requirements for individuals with TMAuria. Patients with TMAuria may be treated with riboflavin (co-factor). The consequences of polymorphic variants of the *FMO3* gene for TMA metabolism may be understood and applied the metabolism of other nitrogen-containing *FMO3* substrates and common medications.

#### **Treatment of individuals with TMAuria**

Individuals with TMAuria may be supplemented with riboflavin. The vitamin riboflavin (vitamin B2) is the cofactor for the FMO FAD-dependent enzyme family. Supplementation with riboflavin may increase the residual activity of *FMO3* and other FMO isoforms known to oxygenate TMA as observed in other disorders. FMO enzymes are known to be inducible by substrate loads and hormones (Cashman J (1995) Chem Res Toxicol 8:166-181). Affected probands may be studied. The

patients may take a once daily dose of riboflavin 200 mg for a period of two months. A baseline urine sample for TMA and TMA N-oxide (FAB-MS) may be measured and at intervals of 4, 6 and 8 weeks for measurement of effect.

The three *FMO3* polymorphisms (E158K, V257M and E308G) may be characterized further. These polymorphisms may exert a clinical effect on TMA oxygenation, applicable perhaps to other *FMO3* substrates including commonly used medication. DNA samples from 70 extended French Canadian families (450 individuals) from the Chicoutimi region of Quebec; (Hypertension sib-pair analysis study). have been genotyped for the three polymorphisms, and approximately 20% of individuals are homozygous or compound heterozygous for one or more of these polymorphisms. Individuals with these genotypes may exhibit a difference in TMA oxidation (used as a marker of decreased N-oxygenation). A rapid FAB-MS assay for TMA and its N-oxide may be used to assess TMA and TMANO in the informative cases. A detailed drug history may also be taken from these individuals to assess whether they are taking other medications likely to be *FMO3* substrates for future pharmacogenetic studies.

From a large cohort of individuals with TMAuria worldwide (confirmed cases in North America and Australians) plasma choline, acetylcholine, phosphatidylcholine, and TMA and TMANO may be measured in urine in controls (adult and pediatric). This may also be performed for individuals with untreated TMAuria and individuals on a low choline diet. Dietary evaluation of daily choline intake (free choline, lecithin, phosphocholine, phosphatidylcholine) may be analyzed using a 3-day dietary recall for the days



prior to the blood test. The choline content of foods may be analyzed and correlated with TMA oxidation results and genotype. As choline is oxidized to betaine, important in homocysteine remethylation, total homocysteine may also be measured in individuals on a choline-restricted diet. TMA and its N-oxide may be measured using the stable isotope FAB method using a 5 cc urine aliquot. <sup>15</sup>N TMA and TMANO may be used as internal standards. Choline, phosphatidylcholine and acetylcholine may be measured from a blood sample extract using electrospray tandem mass spectrometry. Measurements of urinary TMA and its N-oxide may be used also to determine the riboflavin effect and the in vivo effects of polymorphisms, as mentioned above.

#### 15 **Statistical analysis**

From data derived from frequency of genotypes as illustrated in Table 7, the number of individuals that will have informative genotypes may be estimated (presence of greater than 2 polymorphisms (*cis* or *trans*)); 2 variant alleles: (30%), 3: (14.3%), 4: (2.7%), 5 or more: (less than 1%). The estimated sample size of 76 (allowing for non-compliance) may permit adequate comparison between cases and controls. The Student's t test may be used to test the hypothesis that the group of individuals with variant genotypes have a significantly lower mean percentage of N-oxidation than controls. If the sample size permits, the study group may be divided into those that carry 2, 3 or 4 polymorphic alleles and the t-test performed on the distribution of N -oxygenation for each of these categories compared to the central distribution.

These studies may improve our understanding and treatment of TMAuria and our understanding of the

medical relevance of the polymorphisms for TMA metabolism applicable to other FMO substrates.

**Table 7**  
**Genotypes of Possible Pharmacogenetic Significance**  
**Observed in Chicoutimi Region**

Polymorphisms	Allele 1	Allele 2
E158K	2	2
V257M	1	1
E308G	1	1
E158K	2	2
V257M	1	1
E308G	1	2
E158K	1	2
V257M	1	1
E308G	2	2
E158K	2	2
V257M	1	1
E308G	2	2
E158K	1	2
V257M	1	2
E308G	1	2
E158K	1	2
V257M	2	1
E308G	1	2
E158K	1	1
V257M	2	2
E308G	1	1
E158K	1	2
V257M	2	1
E308G	1	1
E158K	1	1
V257M	2	2
E308G	1	2
E158K	2	2
V257M	1	2
E308G	1	1
E158G	2	2
V257M	1	2
E308G	2	2
E158G	1	2
V257M	1	2
E308G	1	2

5     1 designates wild allele, 2 designates variant allele

EXAMPLE IV

**Polymorphisms of the flavin containing monooxygenase 3  
(*FMO3*) gene as a risk factor for essential  
hypertension in French Canadian**

5           Interindividual variation in blood pressure is  
genetically determined resulting from the interaction  
of susceptibility alleles and environmental exposures.  
We previously documented that the rare mutations of  
the *FMO3* gene (a phase 1 xenobiotic detoxicating gene)  
10       cause the inborn error of metabolism Trimethylaminuria  
and may predispose affected individuals to essential  
hypertension (HBP) and abnormal catecholamine  
polymorphisms (E158L (c.488 G-A), E308G (c.923 A-G)  
and V257M (c. 769 G-A)) and haplotypes were phased in  
15       70 extended families from Quebec. Of 8 possible  
haplotypes, 6 were observed. These *in vivo* and *in*  
*vitro* data indicate that these polymorphisms in  
particular haplotypes confer functional  
pharmacogenetic effects.

20           In accordance with the present invention, now  
is reported a case control study of the association  
between variant *FMO3* haplotypes and early onset HBP (<  
55 years) in a Quebec French Canadian population. The  
distribution of haplotypes was determined between (1)  
25       HBP probands (n = 60), (2) HBP relatives (n = 229),  
(3) non-HBP control relatives (n= 145) and (4)  
unrelated non-HBP French Canadian controls (n = 133).  
There was a significant difference noted between the  
distribution of haplotypes between groups (1) and (4)  
30       (p = 0.026). The presence of one variant haplotype in  
individuals conferred a relative risk of HBP of 1.22  
variant haplotypes. These data suggest that the above  
common polymorphisms of the *FMO3* gene in the presence  
of adverse environmental exposures may increase the  
35       risk of individuals in Quebec to early onset HBP.

While the invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications and this application is intended to

5 cover any variations, uses, or adaptations of the invention following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention

10 pertains and as may be applied to the essential features hereinbefore set forth, and as follows in the scope of the appended claims.

**WHAT IS CLAIMED IS:**

1. A method for detecting an altered metabolism of a substrate of a flavin-containing monooxygenase (FMO) enzyme or an isoform thereof in a patient, the method comprising detecting at least one of a mutation and a polymorphic variant of a gene encoding said FMO enzyme in a sample from said patient, whereby said at least one of said mutation and said polymorphic variant is indicative of an altered metabolism for said substrate.
2. A method for detecting a susceptibility of a patient to a substrate of a flavin-containing monooxygenase (FMO) enzyme or an isoform thereof in an patient, the method comprising detecting at least one of a mutation and a polymorphic variant of a gene encoding said FMO enzyme in a sample from said patient, whereby said at least one of said mutation and said polymorphic variant is indicative of a susceptibility to said substrate.
3. A method for detecting a predisposition of a patient to a disorder associated with an (adverse) exposure to a heteroatom-containing chemical compound, an intermediate or a metabolite thereof associated with carcinogenesis or having a toxic, pro-carcinogenic or carcinogenic potential, said method comprising detecting at least one of a polymorphic variant and a mutation of a gene encoding a flavin-containing monooxygenase (FMO) enzyme or an isoform thereof in a sample from said patient, whereby said at least one said polymorphic variant and said mutation

is indicative of exposure to the chemical compound, the intermediate or the metabolite thereof.

4. A method for detecting a predisposition to hypertension in a patient, said method comprising detecting at least one of a mutation and a polymorphic variant of a gene encoding said FMO enzyme in a sample from said patient, whereby said at least one of said mutation and said polymorphic variant is indicative of a predisposition to hypertension.

5. A method according to anyone of claims 1 to 4, wherein said at least one of said mutation and said polymorphic variant inactivates partially or totally the activity of said FMO enzyme.

6. A method according to claim 5, wherein said FMO enzyme consists of isoform 3 (FMO3).

7. A method according to claim 6, wherein the polymorphic variant comprises a polymorphic variant from the group consisting of E158K, V257M and E308G, and the mutation comprises a mutation from the group consisting of P153L, E305X, M66I, E314X, R492W, A52T and R387L.

8. A method according to claim 7, wherein the altered metabolism is associated with an idiosyncratic reaction to the substrate.

9. A method according to claim 8, wherein the altered metabolism is associated with a disorder.

10. A method according to claim 9, wherein the disorder is a cancer.

11. A method according to claim 7, wherein the substrate is a xenobiotic or an endogenous material relative to said individual.

12. A method according to claim 11, wherein said xenobiotic is a drug, a food additive, a pesticide, a plant toxin, an organic chemical compound or an aromatic amine.

13. A method according to claim 12, wherein the substrate is a biogenic amine contained in diet of said individual.

14. A method according to claim 13, wherein said biogenic amine is a tertiary amine.

15. A method according to claim 14, wherein said tertiary amine is trimethylamine (TMA), tyramine or catecholamine.


16. A method according to claim 14, wherein the tertiary amine is trimethylamine (TMA) and wherein the disorder is trimethylaminuria (TMAuria).

17. A method for the treatment of an individual having a disorder associated with an altered activity of a flavin-containing monooxygenase FMO enzyme or an isoform thereof, the method comprising supplementing the individual with riboflavin to increase the altered activity of the FMO enzyme or isoform thereof.

18. A method according to claim 17, wherein the isoform consists of isoform 3 (FMO3).



1/1



## SEQUENCE LISTING

<110> TREACY, Eileen P.  
AKERMAN, Berverly R.  
McGill University

<120> HUMAN FMO3 GENE MUTATIONS AND  
POLYMORPHISMS, AND USES THEREOF

<130> 1770-235PCT

<150> US 60/156,934

<151> 1999-09-30

<160> 10

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 23

<212> DNA

<213> artifical sequence

<220>

<223> sequence to be used as a primer

<400> 1

gacctgatca gtatactcat tta

23

<210> 2

<211> 23

<212> DNA

<213> artifical sequence

<220>

<223> sequence to be used as a primer

<400> 2

aatgggaagt ctgggaaaca ctt

23

<210> 3

<211> 23

<212> DNA

<213> artifical sequence

<220>

<223> sequence to be used as a primer

<400> 3

ttgttccgga catcatgtgt agc

23

<210> 4

<211> 20

<212> DNA

<213> artifical sequence

<220>

<223> sequence to be used as a primer

<400> 4 20  
tccctgctgt ggaagcattt

<210> 5  
<211> 20  
<212> DNA  
<213> artifical sequence

<220>  
<223> sequence to be used as a primer

<400> 5 20  
ttccagaagt ggctcctggg

<210> 6  
<211> 23  
<212> DNA  
<213> artifical sequence

<220>  
<223> sequence to be used as a primer

<400> 6 23  
gcttgaatct tgcattcatc tgc

<210> 7  
<211> 23  
<212> DNA  
<213> artifical sequence

<220>  
<223> sequence to be used as a primer

<400> 7 23  
ccttatcaat ttatatatgg acc

<210> 8  
<211> 23  
<212> DNA  
<213> artifical sequence

<220>  
<223> sequence to be used as a primer

<400> 8 23  
ggaccttgta actaggatta ttg

<210> 9  
<211> 23  
<212> DNA  
<213> artifical sequence

<220>  
<223> sequence to be used as a primer

<400> 9 23  
gaaatgccat actgacccca tgg

<210> 10  
<211> 23  
<212> DNA

<213> artifical sequence

<220>

<223> Sequence to be use as a primer

<400> 10

tagcaaagcc cctgtctggg tat

23